Neogen Chemicals Ltd Q1 FY27 Results

₹250.3 Cr confirmed; prior Q was lower on base

₹19 Cr in Q1 vs ₹5 Cr prior Q1; implies FY25 ~₹38 Cr so 50% claim valid

Reported 19.3% OPM with +260 bps YoY; acknowledged temporary headwinds not yet materially present

Volume-driven +₹15 Cr from Q1, capacity at full utilization confirmed; guidance raised ₹75 Cr midpoint

Q1 ₹19 Cr (mostly salts); trajectory implies ₹281 Cr in H2, heavy Q3-Q4 ramp. Contingent on customer production ramp-up starting Nov 2026

Revised from ₹875-950 Cr to ₹950-1,050 Cr midpoint after Q1 demonstration of peak organo-lithium utilization and cost pass-through success.

₹300 Cr full-year guidance maintained from prior call. Q1 at ₹19 Cr requires ₹281 Cr H2 (6.3x Q1 run-rate), entirely contingent on customer production timeline.

Introduced ₹2,400-2,900 Cr battery revenue by FY29 (vs. prior vague 'tens of thousands of Cr' comment). Backed by CAPEX completion and customer ramp visibility.

Base business targeting 140-150 days by FY28 (vs. current elevated ~160+ days). Battery at 90 days. Full year OCF improvement deferred to FY29.

₹2,500-3,000 Cr by FY29 for current CAPEX, but 5-year demand = ₹50,000+ Cr range with international salt/additives. Aiming 50-50 battery/legacy split long-term.

Lithium-ion remains most efficient. Sodium-ion for niche use cases. Electrolyte plant can switch to sodium-ion; no major impact. Japanese + homegrown tech, no China dependency.

₹200 Cr salts + ₹100 Cr electrolyte. Formula-based on lithium carbonate ₹15-25/kg stable range. Current spot ₹20 is formula price baseline. 70% of shipments from Nov 2026 onward.

Largely volume: organo-lithium hit peak 300 t/month utilization; inorganic (lithium recycle) also grew. ~₹15 Cr price benefit, rest volume. Capacity increase 2.5x from takeover in FY24.

Primarily debt reduction; also keeping firepower for future opportunities (battery PLI, organo-lithium expansion, R&D). Full paydown = ₹40-50 Cr annual interest saving at 8-8.5% rate.

Scheme not finalized; cannot quantify. Main intent: support localization, remove price disparity vs. international. Will pass benefit to customers to maintain competitiveness.

4 of 6 gigafactories approved; 5th also interested post-Pakhajan. Even 50% gigafactory utilization = our full utilization target. Demand exists; manufacturing ramp is the constraint.

Older inventory benefited from sales; very difficult to quantify exact impact.

Organo-lithium grew but QoQ already ramping (Q3-Q4 FY26 at 70-80% utilization, now at peak). YoY shows large jump due to step-up. Organo supports inorganic growth via lithium recycle byproduct.

Not yet guided. Salt at 70-80% utilization, electrolyte 30-50%. Strong case for >₹1,000 Cr but will provide at year-end.

FY29 is the inflection year. Base business targeting 140-150 days by FY28, battery at 90 days from inception. FY29 will be optimized full year with full battery utilization.

No seasonality in pharma (largest 70%+). Demand grown 12x in 2 years post-takeover via diversification. Pharma + semiconductor are biggest drivers. Agro and others ramping.

Will NOT export finished electrolyte; only components (salts, additives, solvents) which are stable. Electrolyte for local market only.

Peak debt before QIP ~₹1,800 Cr; post-QIP if fully used = ₹1,200-1,300 Cr. Insurance proceeds + working capital improvement should reduce to ₹1,000-1,500 Cr. QIP not just for debt; also capacity headroom.

Both. Maximize in-house electrolyte first (customer consultation), but international customers remain focus. Volumes will flex based on domestic vs international demand.

Cannot calculate on-the-fly. Battery 90 days (₹2,500 Cr) + base 140 days (₹1,200 Cr) minus current balance. Already factored into model but exact number deferred.

US is biggest or equal to India. 5 major electrolyte makers; 4 already approved Neogen. Advantage: established tech (Mitsubishi, Morita), rapid scale vs greenfield, 100 GWh capacity headroom.

Driven by organo-lithium full utilization achieved Q1, capacity expansion planned Q2. Dahej ramp will contribute incrementally H2. Q1 baseline + conservative ramp-up assumptions.

Q1 baseline ₹19 Cr requires ₹281 Cr H2 (6.3x step-up). Contingent on customer production ramps Nov 2026 onward; 4 customers approved but manufacturing timelines fluid.

Based on 30 GWh electrolyte + 40 GWh salt capacity design + international demand. Contingent on ACC PLI ramp, US non-FEOC transition, and customer qualifications.

Deferred to year-end guidance; indicates management uncertainty on customer production ramp trajectory. Salt secured by international contracts but electrolyte dependent on domestic gigafactory ramps.

Q1 at 19.3% but temporary tailwinds (inventory gain, toll mfg not yet at run-rate). Guidance conservative; reflects Dahej partial utilization and supply chain headwinds.

Dahej at full run-rate + cost base normalization + product mix optimization toward large-volume molecules. CSM recovery also contributes.

Based on formula-based pricing with lithium pass-through. Interim margins dependent on customer ramp trajectory and lithium prices (currently stable at ₹15-25/kg).

Remaining ₹500 Cr from debt + Morita equity (USD 20M) + ₹40-50 Cr Neogen equity. Financial closure achieved; execution on schedule.

Incremental CAPEX; relatively small CapEx due to existing site infrastructure. Expansion to be decided end Q2/Q3 after confirming 1-2 more quarters of peak utilization.

Management targeting late FY27/early FY28 investment decision to meet FY29 capacity ramp. Contingent on FY28 demand visibility.

₹300 Cr FY27 battery guidance is 40% of total company revenue; only ₹19 Cr in Q1 means ₹281 Cr H2 (6.3x step-up). Contingent on 4-6 ACC PLI gigafactories and US non-FEOC customers reaching production ramp Nov 2026-Q4. Any 2-3 month slip compounds miss.

Despite strong EBITDA (₹48 Cr), company has negative 5-year cumulative OCF of -₹93 Cr even including insurance inflow. Current working capital cycle ~160 days (elevated from 90-day battery target). FY27-28 will see concurrent growth, Dahej ramp-up, battery scale-up—all high working capital activities. Peak debt expected ₹1,800 Cr before QIP.

Dahej replacement plant is critical to base business growth guidance (₹950-1,050 Cr FY27). Reconstruction 95% complete, trial runs underway, Q2 commercial production targeted. Any commissioning delay, yield issues, or customer qualification failures would derail base business guidance and CSM recovery (dependent on Dahej restart).

Battery business growth (especially domestic electrolyte) tied to ACC PLI battery cell manufacturer ramp-up and proposed Government PLI scheme for battery components. PLI scheme not yet finalized; benefits magnitude, structure (CAPEX vs OPEX), and timing uncertain. Any reduction in PLI allocations or delays in cell manufacturer subsidies could reduce customer competitiveness and demand for battery materials.

Q1 gross margin benefited from older inventory realization at higher prices; exact benefit not quantified but management acknowledged. Battery business pricing tied to lithium carbonate prices (formula-based ₹15-25/kg range). If lithium prices spike or fall sharply, customer pricing negotiations could compress margins. Current spot prices lower than formula, creating customer incentive to negotiate down.

CSM (custom synthesis/toll manufacturing) is a strategic growth pillar (pharma, agro, semiconductor customers engaged) but stalled due to Dahej fire. Recovery timeline pushed to FY28-29 for meaningful ramp. No dedicated CAPEX allocated before FY29-30. Long-term CSM upside (one of five industry verticals for diversity) at risk if customer commitments weaken.